Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 4,491,078 shares, an increase of 9.2% from the January 12th total of 4,112,919 shares. Currently, 2.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 236,822 shares, the days-to-cover ratio is currently 19.0 days.
A hedge fund recently raised its stake in Navidea Biopharmaceuticals stock. Virtu KCG Holdings LLC increased its position in shares of Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 305.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 336,414 shares of the biopharmaceutical company’s stock after purchasing an additional 253,471 shares during the quarter. Virtu KCG Holdings LLC owned approximately 0.21% of Navidea Biopharmaceuticals worth $172,000 at the end of the most recent quarter.
Shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) remained flat at $$0.35 during mid-day trading on Friday. 550,323 shares of the company’s stock traded hands, compared to its average volume of 291,254. Navidea Biopharmaceuticals has a twelve month low of $0.29 and a twelve month high of $0.85. The company has a market cap of $58.46, a price-to-earnings ratio of -5.00 and a beta of -0.76.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.